# Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy 

Source: https://onco.cc/trials/nct06726265/  
OnCo record `nct06726265` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pemetrexed, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Immutep S.A.S., active and no longer recruiting.

## Summary

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) is a phase 3 interventional study registered as NCT06726265 by Immutep S.A.S., with 756 participants planned, started 2025-03-21 and due to reach its primary completion in 2027-06. Interventions recorded: eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed, pembrolizumab (KEYTRUDA®), Placebo. Conditions listed: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06726265
- Phase: 3
- Setting: TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.
- Sponsor: Immutep S.A.S.
- Enrolled: 756

## Sources

- ClinicalTrials.gov NCT06726265: https://clinicaltrials.gov/study/NCT06726265

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Immutep](https://onco.cc/companies/immutep/)

---
JSON: https://onco.cc/api/v1/entities/nct06726265.json